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Abstract 
Introduction: The American Heart Association (AHA)/American College of Cardiology 
(ACC) guidelines for the classification of heart failure (HF) are descriptive but lack precise 
and objective measures which would assist in categorising such patients. Our aim was 
two fold, firstly to demonstrate quantitatively the progression of HF through each stage 
using a meta-analysis of existing left ventricular (LV) pressure-volume (PV) loop data and 
secondly use the LV PV loop data to create stage specific HF models. 
Methods and Results: A literature search yielded 31 papers with PV data, representing 
over 200 patients in different stages of HF. The raw pressure and volume data were 
extracted from the papers using a digitising software package and the means were 
calculated. The data demonstrated that, as HF progressed, stroke volume (SV), ejection 
fraction (EF%) decreased while LV volumes increased. A 2-element lumped parameter 
model was employed to model the mean loops and the error was calculated between the 
loops, demonstrating close fit between the loops. The only parameter that was 
consistently and statistically different across all the stages was the elastance (Emax). 
Conclusions: For the first time, the authors have created a visual and quantitative 
representation of the AHA/ACC stages of LVSD-HF, from normal to end-stage. The study 
demonstrates that robust, load-independent and reproducible parameters, such as 
elastance, can be used to categorise and model HF, complementing the existing 
classification. The modelled PV loops establish previously unknown physiological 
parameters for each AHA/ACC stage of LVSD-HF, such as LV elastance and highlight that it 
this parameter alone, in lumped parameter models, 
that determines the severity of HF. Such information will enable cardiovascular modellers 
with an interest in HF, to create more accurate models of the heart as it fails. 
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Introduction 
To model LV performance, quantitative data, such as pressure and volume, is vital 
to ensure that any model is an accurate representation of reality. As such, a 
computational model of the LV cannot be built on single parameters alone such as 
left ventricular end-diastolic volume (LVEDV), subjective symptoms such as 
dyspnoea, nor surrogate markers such as natriuretic peptides (NP’s) but direct 
measures of the system being modelled, both anatomical e.g. volume and 
physiological e.g. pressure. 
Previous attempts to model the HF, and the effect of potential therapies, have 
applied hypothetical haemodynamic states according to symptomatic New York 
Heart Association (NYHA) class rather than actual patient data, from individuals 
or populations. The NYHA class, whilst useful clinically, correlates poorly with 
even non-invasive measures of LV performance [1,2]. Current computational 
models of HF, regardless of complexity, choose arbitrary parameters for the LV 
such as reducing contractility by 50% or boundary conditions such as resistance 
and compliance from healthy populations. Clearly, it is not just the ‘‘pump’’ that 
fails during HF, but also the vasculature, among other systems, and each may 
augment the decline of the other. The authors aimed to provide specific LV 
performance and systemic vascular data on a population basis, to track the 
progression from a healthy to a failing heart. In doing so, for the first time, give 
the modelling community access to disease and severity specific variables derived 
from real patients, to enable the creation of more accurate models. 
In 2001, the joint American Heart Association (AHA)/American College of 
Cardiology (ACC) guidelines categorised for the first time HF and its progression 
in terms of pathophysiology (seetable 1). This was intended to ‘‘complement’’ the 
pre-existing NYHA functional classification and the development of HF, from risk 
e.g. hypertension (Stage A) to end-stage e.g. requiring transplant (Stage D) [3]. 
Whilst the guidelines have subsequently been updated, the classification remains 
qualitative and is often misunderstood [4, 5]. The addition of quantitative measures 
for each stage could be used to more accurately chart the pathophysiology and 
enable the development HF models based on objective parameters. Such measures 
may also improve risk stratification and predict response to clinical interventions. 
To date, attempts to categorize patients into individual AHA/ACC stages have 
focussed on indirect measures, such as NP’s, which nonetheless improve 
prognostication [6]. 
The authors wished to define quantitatively each AHA/ACC stage of HF and so 
for the first time define the risk and the onset and progression of left ventricular 
Table 1. The American Heart Association/American College of Cardiology Heart Failure classification From Jessup et al. (2009) [4]. 
Stage Description Examples 
A Risk of heart failure but without structural heart disease e.g. Hypertension 
B Structural heart disease without signs or symptoms e.g. Previous myocardial infarction 
C Structural heart disease with prior or current symptoms e.g. Patients requiring routine drugs 
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D Refractory heart failure requiring specialist intervention e.g. Heart transplant 
doi:10.1371/journal.pone.0114153.t001 
systolic dysfunction heart failure (LVSD-HF) according to objective changes in left 
ventricular physical properties represented by the left ventricular pressurevolume 
loops. The choice of the pressure-volume (PV) loop is based on its direct 
description of the performance of the LV in real-time and for reasons mentioned 
above, quantifying LVSD-HF by other parameters such as LV volume or symptoms 
is insufficient for modelling purposes. 
For this study, we concentrated on the chronic LVSD-HF population based on 
both pragmatic approach, and a more therapeutic consideration since only patients 
with LVSD-HF have interventions that are associated with significant impact on 
morbidity and mortality. There have been many studies looking at LV PV loops in 
patients with heart disease, but this is the first time they have all been collated, 
compared and modelling parameters derived. For comparision and completeness, a 
healthy normal group (stage O) was created also, not contained in the AHA/ACC 
guidelines, 
Methods PV loops 
The methodology for PV loop acquisition has been described in detail previously 
[7,8]. Briefly, a specialised catheter is inserted via the femoral artery to the apex of 
the LV cavity under fluoroscopy (see figure 1). Real-time measurement of pressure 
is performed using a micro manometer on the catheter, and of volume, using the 
conductance method. The conductance method refers to the usage of linearly placed 
electrodes on the catheter, each measuring segmental volumes, this utilises 
excitation and recording electrodes, the former generate an electric field, and the 
latter measure a change in voltage proportional to resistance. A mathematical 
formula is then used to calculate the total volume of the LV cavity, which takes 
into account the distance between the electrodes and the blood pool resistivity. 
An online literature search of Pubmed, Web of Knowledge, Medline and 
Google, using the search term ‘‘pressure volume loop’’ was conducted and the 
references were studied to check that they met criteria to be included in the final 
analysis (see figure 2). 
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Figure 1. Combined pressure-volume catheter (in black) positioned in the left ventricular cavity. The micromanometer 
can be seen at level 3 and the 6 electrodes (white markers) mapping the volume of each of the 5 segments (reproduced 
with permission, from Steendijk et al. (2004)). 
 
doi:10.1371/journal.pone.0114153.g001 
Inclusion criteria 
Studies with complete LV PV loops in adult humans in English. 
(and) Studies representing any AHA/ACC stage including healthy normal 
subjects. 
(and) HF, if present, due to chronic LVSD-HF only. 
Exclusion criteria 
Diastolic HF or HFPEF. 
HF secondary to an uncommon cause such as Chagas’ disease. 
An unclear past medical, symptom or drug history, meaning HF stage was vague. 
No pictorial representation of an entire loop, such as a diastolic limb only. 
Acquisition during experimental treatment only without a baseline measure 
Of the papers identified, 97 were potentially useable, but only 31 met the 
inclusion, and not the exclusion, criteria and so were included in the final analysis, 
accounting for 203 patients [9–38]. 
Engauge digitizing software (http://digitizer.sourceforge.net/) was then used to 
upload the graphical PV loop images from the original studies and convert them 
into numerical data, as seen in figure 3 [39]. This freeware allows users to upload 
a graphical image, such as a PV loop, in variety of formats such as a Joint 
Photographic Experts Group (JPEG) file, and convert a pictorial image into 
numerical data. After loading the file, the parameters of the axes (red crosshairs) 
were chosen, with X corresponding to 80–280 ml and Y 0–150 mmHg 
respectively. The PV loop is then digitised automatically (blue crosshairs), turning 
the PV loop picture into a series of individual pressure and volume data points, 10 
points per limb of the curve, giving a total of 40 data points for each PV loop. The 
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LV PV loops from each LVSD-HF stage were converted into digital values and 
these were then tabulated and the mean for each calculated. 
 
Figure 2. Flow diagram demonstrating inclusion and exclusion criteria for left ventricular pressure-volume loop studies. HFPEF 5 heart failure with preserved ejection 
fraction, LV 5 left ventricle, LVSD 5 left ventricular systolic dysfunction, PV 5 pressure volume, 
 
doi:10.1371/journal.pone.0114153.g002 
 
 PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 6 / 22 
Closing the Loop 
Figure 3. Screenshot from Engauge - on the left, the pressure volume loop is seen, with red cross hairs denoting X and Y axes, and blue crosshairs which correspond 
with the numerical values of pressure and volume seen in the table on the right. LV 5 left ventricle. 
 
doi:10.1371/journal.pone.0114153.g003 
Modelling the PV loops 
Various computational models exist in the engineering literature of the 
cardiovascular system, from simple lumped parameter to more complex 3 
dimensional models. The purpose of the lumped parameter models is to describe 
the changes in pressure, volume and flow that occur over the cardiac cycle as a 
function of cardiac performance and systemic afterload. This paper presents the 
numerical values of the four parameters in the simplest possible representation of 
the heart and systemic circulation; LV elastance (maximum and minimum), total 
peripheral resistance and systemic vascular compliance, the components of which 
are described below. The progression of LVSD-HF is thus expressed in terms of 
the evolution of these four parameters. Furthermore it is suggested that the values 
of the components that represent the systemic afterload might be used to determine 
appropriate boundary conditions for the modeller who is interested in using such 
representations for complex 3D models of the left ventricle, which still rely on a 
specific afterload for the LV to ‘‘push’’ against. 
A lumped parameter model represents complex systems such as the 
cardiovascular system as a hydro-electrical analogue. In particular, the Windkessel 
model (meaning ‘‘air chamber’’ in German) contains a two element afterload, a 
capacitor representing the elastic property of the large arteries which determines 
systemic vascular compliance (C) and a resistor representing the frictional loss in 
the smaller vessels e.g. arterioles which determine the total peripheral resistance 
(R). The LV is represented by a variable elastance (E) model, where by the LV 
pressure is a function of the LV elastance and the change in LV volume from its 
resting state, in this model E is represented by 2 values, Emax being representative 
of peak systolic LV contractility and Emin being representative of end diastolic LV 
stiffness. Using software such as OpenCell, (http://www.cellml.org/tools/opencell) 
such models can be run and the input variables of E, R and C manipulated, for 
example, to model hypertension one could reduce the compliance and increase the 
resistance of the vasculature, whilst leaving the value of E unaltered. The resulting 
outputs of LV pressure and volume can be exported to a database, extracted from 
one cardiac cycle and then converted into a PV loop. 
For this study, a lumped parameter model with a variable elastance LV and 2 
element (R and C) Windkessel afterload was chosen to model the LV in LVSD-HF 
[40]. It was chosen due to its elegance in representing the cardiovascular system, 
simplicity in manipulation, low computational demands and experience within the 
research group. This was downloaded from the CellML (http://www.cellml. org/) 
model repository, which is a free to access store of computer based mathematical 
models, and run using OpenCell, an open source platform for working with CellML 
models, seefigure 4 [41]. In this model the left atrium (ELA) and left ventricle (ELV) 
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are represented by variable capacitors to model the pumping action of the left side 
of the heart, the mitral (mi) and aortic (ao) valves are represented by diodes to model 
unidirectional flow, the total peripheral resistance by a resistor, systemic vascular 
compliance by a capacitor and blood vessels by wire allowing for flow of electrons, 
representing the flow of blood. 
 
Figure 4. Schematic diagram of Zero-D model of the cardiovascular system, with the heart comprised of variable 
capacitors representing elastance of the LA (ELA) and LV (ELV) and the aortic (ao) and mitral valves (mi) by diodes. The 
systemic loop is comprised of a systemic arterial compliance represented by a capacitor (CV) and total peripheral 
resistance by a resistor (RV). 
 
doi:10.1371/journal.pone.0114153.g004 
To model the mean AHA/ACC PV loops, the Matlab (Mathworks, MA, USA) 
optimisation toolbox was used to find the combination of parameters that best fitted 
the data. This toolbox enabled running the lumped parameter model as an iterative 
process, whilst varying each variable (Emax, Emin, R and C) until the best-fit 
model for the patient derived mean LV PV loop for each stage was created. The 
resulting model PV loop data was exported to a spreadsheet and compared against 
the mean loops (see below). 
Statistics 
Statistical analysis was carried out using Microsoft Excel 2010 software 
(Microsoft, CA, USA). Parametric data is given as mean (¡ SD). Comparison of 
data between LVSD-HF stages using an unpaired 2 tailed Students t-test and p 
values of ,0.05 were considered significant. 
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Results Mean PV loops 
The majority of the patients making up each category are males in their late fifties 
(see table 2). Some AHA/ACC LVSD-HF stage groups have more patients than 
others and group A is dominated by ischaemic heart disease (IHD), rather than 
other risk factors such as obesity or diabetes. However, there is a balanced 
distribution of LVSD-HF aetiologies in both groups C and D, with both ischaemic 
and idiopathic dilated cardiomyopathy (DCM) accounting for approximately 50% 
each. 
Figure 5 demonstrates all of the individual patient loops together with the mean 
loops from each stage. As one can see from figure 6, there is a conformational 
difference not only between all stages O-D but also between those asymptomatic 
or at risk groups A-B and those in symptomatic LVSD-HF groups C-D. Table 3 
shows that as one progresses from normal LV function to symptomatic LVSD-HF 
due to left ventricular systolic dysfunction: the LV volumes and diastolic pressures 
rise, and the stroke volume (SV), ejection fraction (EF%) and systolic pressure fall. 
Furthermore, the maximal elastance of the LV falls, as the disease progresses. 
For clarity, we have just shown the raw and mean loops from one stage, AHA/ 
ACC D (figure 7). It is evident that even within AHA/ACC stages there is 
individual variation, both in terms of LV pressure and volume. Figure 8 
demonstrates the standard error for each of the PV points derived from patients in 
this stage, reflecting this large spread. Table 4 demonstrates, that there is no 
statistically significance differences between stages O and A or B, but together they 
are significantly different from stages C and D in all variables, other than other than 
minimal elastance. There are no significant differences between stages C and D. 
Modelled PV loops 
For the modelled PV loops (see figure 9) there is a more accurate fit for the loops 
representing the earlier AHA/ACC LVSD-HF stages, which reduces as the LV 
contraction deteriorates and the stage progresses. Table 5, shows how the modelled 
LV elastance falls from a normal LV to end-stage HF due to LVSD; the volume of 
the LV increases but yet the resistance and compliance of the systemic vasculature 
remain unchanged. 
Table 6 demonstrates, that there is no statistically significance difference 
between model parameters between stages O and A or B, but they are significantly 
different from stages C and D in Emax only. There were no significant differences 
between stages C and D. 
Using Matlab (Mathworks, MA, USA), we compared the area error for the 
modelled loops to the mean, to give a measurement of accuracy (see table 5 and 
figure 10). This method compared the area occupied by the mean PV loop derived 
from the patient (white) data against the mean PV loop created from the lumped 
parameter model (black) to give an overlapping area (grey). Because the modelled 
loops are based on mean data, modelling the size, rather than the shape of the PV 
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loops is important. Thus we compared the overlapping area of the mean and 
modelled loops as a measure of closeness of fit against that area which did not 
overlap. The area, which was not overlapping e.g. the error, was calculated as a 
percentage of the total, giving an overall mean error for all stages of less than 10%. 
Comparing the mean and modelled PV loop data statistically; there were no 
significant differences at any stage (not shown). 
Table 2. Demographic information on the patients comprising the left ventricular pressure volume loops. 
AHA/ACC HF Stage   O A B C D 
Demographics Number of patients Total population 20 144 88 62 129 
  Patients with loops 2 65 6 42 92 
 Gender % male 75 65 77 88 84 
 Age mean 29 56 59 60 58 
Aetiology HTN %  7    
 IHD %  93    
 MI %   100   
 Ischaemic DCM %    50 54 
 Idiopathic DCM %    50 46 
HTN – hypertension, IHD – ischaemic heart disease, MI – myocardial infarction, DCM – dilated cardiomyopathy. 
 
doi:10.1371/journal.pone.0114153.t002 
 PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 10 / 22 
Closing the Loop 
 
Figure 5. Graph showing the progression of HF by individual PV (thin, pale lines) and averaged (thick, dark lines) loops for all the American Heart Association 
(AHA)/American College of Cardiology (ACC) heart failure (HF) stages including stage O (blue), A (red), B (green), C (yellow) and D 
(purple). 
 
doi:10.1371/journal.pone.0114153.g005 
 
Figure 6. Graph showing the progression of HF by mean PV loops for all the American Heart 
Association (AHA)/American College of Cardiology (ACC) heart failure (HF) stages including stage O 
(solid black diamonds), A (black crosses), B (white circles), C (solid black squares) and D (white triangles). 
 
doi:10.1371/journal.pone.0114153.g006 
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Discussion 
This is the first meta-analysis of all of the existing literature on PV loops in 
LVSDHF, stratified by AHA/ACC stage. This study demonstrated that the 
pressurevolume data in the literature supports the existing theoretical ACC/AHA 
physiological paradigm for LVSD-HF, whereby as the left ventricle fails, it dilates. 
Thus, the contractile force is impaired and the volume it ejects with each beat is 
reduced. This study showed quantitatively the changes between each AHA/ACC 
stage. As the AHA/ACC stages are descriptive and qualitative, particularly stages 
C and D, it is remarkable how the stages could be delineated quantitatively in this 
study. Indeed, it demonstrates the strength of the EF, although typically used in 
echocardiography or cardiac magnetic resonance, as it is the only variable in the 
patient data, that is statistically and significantly different across all the stages, 
other than between O and A. 
For the first time, a LPM has been used to model all the existing PV loop data 
across the entire spectrum of heart disease, from healthy normal individuals to 
patients with end-stage LVSD-HF. The model, whilst simple, performed well, with 
Table 3. Mean left ventricle parameters for each stage of heart failure (with standard deviation in brackets). 
AHA/ACC HF Stage  O A B C D 
LV parameters LVESV (ml) 48 (21) 66 (52) 93 (48) 166 (61) 210 (96) 
 LVEDV (ml) 138 (7) 154 (33) 161 (49) 237 (62) 273 (98) 
 SV (ml) 89 (14) 88 (29) 68 (23) 71 (21) 63 (30) 
 EF (%) 0.65 (0.01) 0.57 (0.10) 0.45 (0.16) 0.32 (0.10) 0.25 (0.10) 
 Elastance (mmHg/ml) 2.23 (0.26) 2.27 (0.29) 1.32 (0.73) 0.63 (0.36) 0.55 (0.23) 
 Stiffness (mmHg/ml) 0.17 (0.01) 0.09 (0.06) 0.10 (0.03) 0.06 (0.04) 0.08 (0.04) 
LV 5 left ventricle, LVESV 5 left ventricular end systolic volume, LVEDV 5 left ventricular end diastolic volume, EF 5 ejection fraction. 
 
doi:10.1371/journal.pone.0114153.t003 
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Figure 7. Graph showing mean pressure volume loop for American Heart Association (AHA)/American College of 
Cardiology (ACC) heart failure (HF) stage D (white triangles) and the spread of the raw loops sourced from the 
literature (grey lines). 
 
doi:10.1371/journal.pone.0114153.g007 
a mean error of less than 10% and gives insight into how the heart, and the systemic 
vasculature fail. 
The lumped parameter model is true in physiological sense. Predictably, the 
pump function of the left ventricle deteriorates as LVSD-HF progresses, the left 
ventricular chamber dilates, the afterload and plasma volume increase, which will 
affect both R and C. The pressure-volume loops showed each stage as expected, 
thus: Stage O is indeed healthy, with normal left ventricular parameters that we 
would expect from a disease-free population. Patients in Stage A, the vast majority 
of whom have IHD, the systolic pressure rises reflecting increased afterload and 
the EF% and SV fall. However, all these parameters are still within normal limits. 
Following an ischaemic insult to the myocardium in Stage B, there is a rise in 
LVEDP reflecting increased stiffness, a fall in systolic pressure due to impaired 
 
Figure 8. Graph showing mean pressure volume loop for each American Heart Association (AHA)/ American College 
of Cardiology (ACC) heart failure (HF) stage (shown as white triangles) and standard error (shown black lines). 
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doi:10.1371/journal.pone.0114153.g008 
Table 4. Statistical comparison of parameters from the patient data for each American Heart Association/American College of Cardiology heart failure stage, using 2-
tailed Student’s T-Test. 
AHA/ACC HF 
Stage 
Parameter Unit O A B C D 
O LVEDV (ml)  p50.31 p50.27 p,0.05 p,0.05 
LVESV (ml)  p50.22 p50.13 p,0.01 p,0.05 
SV (ml)  p50.49 p50.13 p50.11 p,0.001 
EF (%)  p50.19 p,0.05 p,0.001 p,0.001 
Emax (mmHg/ml)  p50.48 p50.05 p,0.001 p,0.001 
Emin (mmHg/ml)  p50.29 p50.19 p50.08 p50.39 
A LVEDV (ml)   p50.37 p,0.001 p,0.001 
LVESV (ml)   p50.05 p,0.001 p,0.001 
SV (ml)   p,0.05 p,0.01 p,0.001 
EF (%)   p,0.01 p,0.001 p,0.001 
Emax (mmHg/ml)   p,0.05 p,0.001 p,0.001 
Emin (mmHg/ml)   p50.47 p,0.001 p50.21 
B LVEDV (ml)    p,0.01 p,0.01 
LVESV (ml)    p,0.01 p,0.001 
SV (ml)    p50.39 p,0.001 
EF (%)    p,0.01 p,0.001 
Emax (mmHg/ml)    p,0.01 p,0.001 
Emin (mmHg/ml)    p,0.001 p50.29 
C LVEDV (ml)     p50.09 
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LVESV (ml)     p50.08 
SV (ml)     p50.40 
EF (%)     p,0.05 
Emax (mmHg/ml)     p50.38 
Emin (mmHg/ml)     p50.18 
AHA 5 American Heart Association, ACC 5 American College of Cardiology EF 5 ejection fraction, LV 5 left ventricle, LVESV 5 left ventricular end systolic volume, LVEDV 
5 left ventricular end diastolic volume, SV 5 stroke volume. 
 
doi:10.1371/journal.pone.0114153.t004 
contractile force and corresponding reduction in both the ejection fraction and the 
stroke volume. What is somewhat surprising is that whilst there is an increase in 
volume from stage C to D, both the systolic and diastolic pressures rise. This is not 
necessarily surprising as the process is not a simple mechanical process but it 
reflects the contribution of the compensatory mechanisms driven by the 
sympathetic drive and by the endocrine responses driven by the renninangiotensin-
aldosterone system as well as the sympathetic system. 
The patients in stages A-B are asymptomatic from the LVSD-HF viewpoint, this 
is despite an increase of R and C, and decrease in LV Emax, by 60% (relative to 
Stage O). However, the remaining contractile force is sufficient to meet the 
demands of the body. The difference between the asymptomatic patients with 
structural heart disease (Stage B) and those with symptoms of (Stage C) is the 
reduction in LV Emax by a further 50%. The difference between symptomatic and 
refractory LVSD-HF is a further modest (13%) reduction in Emax (which translates 
into an absolute fall of 75% compared to Stage O). This is an important observation 
that illustrates the delicate tipping point between physiological compensation and 
decompensation. Indeed, as seen statistically, stage C and D were not significantly 
different from one another, but they were on almost every single variable compared 
to stages O-B. This information, whilst logical and perhaps inferred, was previously 
unknown. Also, there was no significant difference between any of the groups in 
Emin, representing LV end-diastolic stiffness, as one might expect, as this was a 
study investigating LVSD-HF, not HFPEF, although diastolic dysfunction can co-
exist with systolic. 
Importantly, the creation of the lumped parameter model variables for the various 
LVSD-HF stages (see table 4), will satisfy both the academic and clinical 
communities. From simple lumped parameter to 3D models of the LV, all use 
predefined boundary conditions, such as elastance, resistance and capacitance, 
regardless of their complexity. From a clinical perspective, a model of the failing 
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heart, should utilise as much patient derived data as possible, not simply use 
arbitrary measures. From a modelling perspective, a model must be based on robust, 
repeatable and high fidelity measures of the system one seeks to represent, not 
symptoms or biomarkers. For the first time in LVSD-HF, this novel work enables 
both parties to use data that is academically rigorous, clinically meaningful and 
enable the creation of patient and disease specific models. Depending on the stage 
of the LVDS-HF, the modellers can choose the variables to fit their theoretical 
cohort. 
Previously, it was felt that the LV afterload, comprising total peripheral 
resistance and systemic vascular compliance had an important role in modelling 
the LV performance accurately. However, this body of work, comprising the 
largest cohort of LVSD-HF models based on real patients to date, demonstrates 
there is no significant different in compliance or resistance between even healthy 
normals and end-stage. This is important as it demonstrates, that in LVSD-HF and 
in this this model at least, the most important factor is Emax or peak 
 
Figure 9. Graph showing the progression of heart failure by mean pressure volume loop for all American Heart 
Association (AHA)/American College of Cardiology (ACC) heart failure stages from O-D (various markers) along with 
the modelled loops (solid black lines). 
 
doi:10.1371/journal.pone.0114153.g009 
Table 5. Lumped parameter model variables and calculated error for each stage. 
Parameter Unit AHA/ACC HF Stage    
  O A B C D 
Emax (mmHg/ml) 2.50 2.20 1.14 0.55 0.52 
Emin (mmHg/ml) 0.08 0.06 0.15 0.04 0.06 
LV Volume (ml) 468 522 771 579 726 
Resistance (mmHgNs/ml) 1.15 1.51 1.50 1.65 1.58 
Compliance (ml/mmHg) 3.19 2.90 5.34 3.87 4.33 
Percentage error (%) 7.5 3.0 7.5 15.0 10.6 
doi:10.1371/journal.pone.0114153.t005 
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contractility of the LV. Of course, in reality, it is well known that increased 
afterload on the heart, due to diseases like hypertension, leads to increase LV wall 
shear stress, left ventricular hypertrophy and if untreated LVSD and eventually 
LVSD-HF. Afterload and compliance will also be influenced by other disease 
processes and medications, which were impossible to control for and very few of 
this patient cohort, particularly in stage A had hypertension. Our findings however, 
further strengthen the importance of using load-independent, repeatable and robust 
measures of LV performance such as elastance when modelling LVSDHF. 
There is wide distribution of the PV loops within each stage, as demonstrated in 
Stage D by figure 6 (other stages are similar, but for brevity they were not shown), 
which means that there is difficulty stratifying the disease condition based on 
current measures of LV function, such as LVEDV or SV. The mean loops from 
stages B-C would also fit within the data range of stage D and the AHA/ACC 
classification. This probably due to the lack of standardisation of LV volume 
against body surface area e.g ml/m2 as undoubtedly in a cohort of over 200 patients, 
there will be large variations in patient size and anatomy. Hence, there is overlap 
amongst the disease stages and accounts for the non-significance difference in LV 
volume between the 5 stages. This further highlights the importance of objective 
differentiation of patient LVSD-HF stages, when creating models, rather than being 
based on the patient’s subjective assessment (although the latter is clinically 
important) and objective echocardiographic measurements used in current clinical 
practice. 
Future work 
It would be interesting to compare the PV loops of patients with HF of different 
aetiologies, such as ischaemic versus idiopathic DCM, and to model the effects of 
various therapies on the different parameters, such as cardiac resynchronisation 
therapy (CRT). Furthermore, comparing those PV loops of patients with different 
isolated risk factors for HF, such as obesity or essential hypertension or with 
differing structural heart diseases such as asymptomatic aortic stenosis or left 
ventricular hypertrophy to see how they progress from symptomless risk to 
symptomatic HF would also be of interest. Unfortunately, such data are not 
Table 6. Statistical comparison of the lumped parameter variables for each American Heart Association/American College of Cardiology heart failure stage model, using 
2-tailed Student’s T-test. 
AHA/ACC HF 
Stage 
Parameter Unit O A B C D 
O Emax (mmhg/ml)  p50.76 p50.81 p,0.001 p,0.001 
 Emin (mmhg/ml)  p50.71 p50.65 p50.98 p50.77 
 LV Volume (ml)  p50.76 p50.81 p50.17 p,0.001 
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 Resistance (mmhgNs/ml)  p50.06 p50.25 p50.48 p50.37 
 Capacitance (ml/mmhg)  p50.67 p50.93 p50.71 p50.80 
A Emax (mmhg/ml)   p50.63 p,0.001 p,0.001 
 Emin (mmhg/ml)   p50.06 p,0.05 p,0.001 
 LV Volume (ml)   p50.27 p,0.05 p50.53 
 Resistance (mmhgNs/ml)   p50.36 p50.21 p50.08 
 Capacitance (ml/mmhg)   p50.41 p50.06 p50.07 
B Emax (mmhg/ml)    p,0.01 p,0.001 
 Emin (mmhg/ml)    p50.16 p,0.001 
 LV Volume (ml)    p50.88 p50.35 
 Resistance (mmhgNs/ml)    p50.88 p50.35 
 Capacitance (ml/mmhg)    p50.63 p50.35 
C Emax (mmhg/ml)     p50.43 
 Emin (mmhg/ml)     p50.25 
 LV Volume (ml)     p50.25 
 Resistance (mmhgNs/ml)     p,0.05 
 Capacitance (ml/mmhg)     p50.9 
doi:10.1371/journal.pone.0114153.t006 
currently available. More PV loops are needed to inform stages O and B, as the 
mean loops and therefore the models, are based on a small number of cases. 
However, it is unlikely that ethical approval for invasive PV loop analysis would 
be granted for healthy subjects. 
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Drawbacks 
Most of the information given about patients was not specific to the loop and so we 
were unable to control for age, body mass, sex, medications and other relevant co-
morbidities (both cardiac, such as mitral regurgitation and non-cardiac, such as 
renal failure), which could have an impact on the loop shape, size and position [42]. 
Some curves were averaged already from a patient population (hence the number 
of patients represented is greater than the number of loops) and what may have 
been AHA D in previous decades, may be considered AHA C today. We could not 
control for any differences in methodology across the papers. Most of the PV loops 
are from middle-aged, probably white, male patients, reflecting the fact the women 
are under-represented in HF clinical trials. We should not assume women, ethnic 
minorities, or patients with conditions not represented e.g. 
obesity, will be the same. As can be seen from figure 6, averaging the means that a 
lot of the raw data is lost and the curves smoothed accordingly, thus a real patient 
 
Figure 10. Graph demonstrating the PV area comparison of the mean loop for American Heart Association/American 
College of Cardiology heart failure stage O (shown in white), the modelled loop (shown in black) and the intercepting 
area (shown in grey). 
 
doi:10.1371/journal.pone.0114153.g010 
in stage D will not necessarily meet the mean values, but may fall within the range 
of values given. Digitizing the PV loops was employed to allow access to the data 
underlying each loop. Due to the duration of time that has passed since the original 
publication of many of the papers, only a small number of authors were contactable. 
Conclusions 
For the first time, the authors have created a visual and quantitative representation 
of the AHA/ACC stages of LVSD-HF, from normal to end-stage. The study 
demonstrates that robust, load-independent and reproducible parameters, such as 
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elastance, can be used to categorise and model HF, complementing the existing 
classification. The modelled PV loops establish previously unknown physiological 
parameters for each AHA/ACC stage of LVSDHF, such as LV elastance and 
highlight that it this parameter alone, in lumped parameter models, that determines 
the severity of HF. This is the largest collection of LV PV loop data, which has 
been used to create stage specific HF models, and as such, will enable 
cardiovascular modellers to create more accurate models of the heart as it fails and 
should be used as a reference for future work in this field. 
Supporting Information 
Checklist S1. Search yield according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses. 
doi:10.1371/journal.pone.0114153.s001 (DOC) 
Diagram S1. Flow diagram for search results according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses. 
doi:10.1371/journal.pone.0114153.s002 (DOC) 
Acknowledgments 
The authors would like to thank Professors Patrick Segers and Christopher 
Hayward, for providing raw PV loop data. 
Author Contributions 
Conceived and designed the experiments: DW YS AB. Performed the experiments: 
DW YS AB. Analyzed the data: DW YS AB. Contributed reagents/materials/ 
analysis tools: DH PL. Wrote the paper: DW YS AB PS AA PL DH SV. 
References 
1. Tsuruta H, Sato T, Shirataka M, Ikeda N (1994) Mathematical model of cardiovascular mechanics for diagnostic 
analysis and treatment of heart failure: Part 1. Model description and theoretical analysis. Med Biol Eng Comput 
32: 3–11. 
2. Tsuruta H, Sato T, Ikeda N (1994) Mathematical model of cardiovascular mechanics for diagnostic analysis and 
treatment of heart failure: Part 2. Analysis of vasodilator therapy and planning of optimal drug therapy. Med 
Biol Eng Comput 32: 12–18. 
3. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, et al. (2001) ACC/AHA Guidelines for the 
Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 
1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 104: 2996–3007. 
4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. (2009) 2009 focused update: ACCF/AHA 
Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in 
collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977–2016. 
 PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 20 / 22 
Closing the Loop 
5. Marco TD, Delgado Iii RM, Agocha A (2004) Confusion at large: incorrect assignment of patients to the AHA/ACC 
stages of heart failure in the ADVANCENT Registry. Journal of Cardiac Failure 10: S96. 
6. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, et al. (2007) Prevalence and prognostic significance 
of heart failure stages: application of the American College of Cardiology/ American Heart Association heart 
failure staging criteria in the community. Circulation 115: 1563–1570. 
7. Kass DA (1992) Clinical evaluation of left heart function by conductance catheter technique. Eur Heart J 13: S57–
64. 
8. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, et al. (1984) Continuous measurement of left 
ventricular volume in animals and humans by conductance catheter. Circulation 70: 812–823. 
9. Thormann J, Huting J, Kremer P, Wissemann J, Bahawar H, et al. (1990) Do class 1 antiarrhythmic drugs impair 
myocardial contractility? The class 1A example of ajmaline (conductance catheter technique). J Cardiovasc 
Pharmacol 16: 182–190. 
10. Schreuder JJ, Biervliet JD, van der Velde ET, ten Have K, van Dijk AD, et al. (1991) Systolic and diastolic pressure-
volume relationships during cardiac surgery. J Cardiothorac Vasc Anesth 5: 539–545. 
11. Aroney CN, Herrmann HC, Semigran MJ, Dec GW, Boucher CA, et al. (1989) Linearity of the left ventricular end-
systolic pressure-volume relation in patients with severe heart failure. J Am Coll Cardiol 14: 127–134. 
12. Dekker ALAJ, Phelps B, Dijkman B, van Der Nagel T, van Der Veen FH, et al. (2004) Epicardial left ventricular lead 
placement for cardiac resynchronization therapy: Optimal pace site selection with pressure-volume loops. J 
Thorac Cardiovasc Surg 127: 1641–1647. 
13. Feldman MD, Pak PH, Wu CC, Haber HL, Heesch CM, et al. (1996) Acute Cardiovascular Effects of OPC-18790 in 
Patients With Congestive Heart Failure: Time- and Dose-Dependence Analysis Based on Pressure-Volume 
Relations. Circulation 93: 474–483. 
14. Ferrari M, Kadipasaoglu KA, Croitoru M, Conger J, Myers T, et al. (2005) Evaluation of myocardial function in 
patients with end-stage heart failure during support with the Jarvik 2000 left ventricular assist device. Journal of 
Heart and Lung Transplantation 24: 226–228. 
15. Hayward CS, Kalnins WV, Rogers P, Feneley MP, Macdonald PS, et al. (1999) Left ventricular chamber function 
during inhaled nitric oxide in patients with dilated cardiomyopathy. Journal of Cardiovascular Pharmacology 34: 
749–754. 
16. Herrmann HC, Ruddy TD, William G, Strauss HW, Boucher CA, et al. (1987) Inotropic effect of enoximone in 
patients with severe heart failure: demonstration by left ventricular end-systolic pressurevolume analysis. J Am 
Coll Cardiol 9: 1117–1123. 
17. Kashimura T, Kodama M, Aizawa Y (2007) Left ventricular pressure–volume loops during mechanical alternans 
in a patient with dilated cardiomyopathy. Heart 93: 151. 
18. Kass DA, Baughman KL, Pak PH, Cho PW, Levin HR, et al. (1995) Reverse remodeling from cardiomyoplasty in 
human heart-failure - external constraint versus active assist. Circulation 91: 2314– 2318. 
19. Kawaguchi AT, Sugimachi M, Sunagawa K, Ishibashi-Ueda H, Karamanoukian HL, et al. (2001) Perioperative 
hemodynamics in patients undergoing partial left ventriculectomy. J Card Surg 16: 48–55. 
20. Kelly R, Ting C, Yang T, Liu C, Maughan W, et al. (1992) Effective arterial elastance as index of arterial vascular 
load in humans. Circulation 86: 513–521. 
21. Kim MH, Devlin WH, Das SK, Petrusha J, Montgomery D, et al. (1999) Effects of ß-Adrenergic Blocking Therapy 
on Left Ventricular Diastolic Relaxation Properties in Patients With Dilated Cardiomyopathy. Circulation 100: 
729–735. 
22. Lorusso R, Milan E, Volterrani M, Giubbini R, van der Veen F, et al. (1997) Cardiomyoplasty as an isolated 
procedure to treat refractory heart failure. Eur J Cardiothorac Surg 11: 363–372. 
23. MacGowan GA, Haber HL, Cowart TD, Tedesco C, Wu C, et al. (1998) Direct Myocardial Effects of 
OPC-18790 in Human Heart Failure: Beneficial Effects on Contractile and Diastolic Function Demonstrated by 
Intracoronary Infusion With Pressure–Volume Analysis. Journal of the American College of Cardiology 31: 
1344–1351. 
 PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 21 / 22 
Closing the Loop 
24. Magorien D, Shaffer P, Bush C, Magorien R, Kolibash A, et al. (1983) Assessment of left ventricular pressure-
volume relations using gated radionuclide angiography, echocardiography, and micromanometer pressure 
recordings. A new method for serial measurements of systolic and diastolic function in man. Circulation 67: 844–
853. 
25. Redington AN, Gray HH, Hodson ME, Rigby ML, Oldershaw PJ (1988) Characterisation of the normal right 
ventricular pressure-volume relation by biplane angiography and simultaneous micromanometer pressure 
measurements. Br Heart J 59: 23–30. 
26. Remmelink M, Sjauw KD, Henriques JP, Vis MM, van der Schaaf RJ, et al. (2009) Acute left ventricular dynamic 
effects of primary percutaneous coronary intervention from occlusion to reperfusion. J Am Coll Cardiol 53: 1498–
1502. 
27. Schreuder JJ, Maisano F, Donelli A, Jansen JRC, Hanlon P, et al. (2005) Beat-to-Beat Effects of Intraaortic Balloon 
Pump Timing on Left Ventricular Performance in Patients With Low Ejection Fraction. Ann Thorac Surg 79: 872–
880. 
28. Schreuder JJ, van der Veen FH, van der Velde ET, Delahaye F, Alfieri O, et al. (1995) Beat-to-Beat Analysis of Left 
Ventricular Pressure-Volume Relation and Stroke Volume by Conductance Catheter and Aortic Modelflow in 
Cardiomyoplasty Patients. Circulation 91: 2010–2017. 
29. Smith M, Russell RO, Feild BJ, Rackley CE (1974) Left Ventricular Compliance and Abnormally Contracting 
Segments in Postmyocardial Infarction Patients. Chest 65: 368–378. 
30. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX (2004) The calcium sensitizer levosimendan improves the function 
of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. 
Journal of the American College of Cardiology 43: 2177–2182. 
31. Steendijk P, Tulner SA, Bax JJ, Oemrawsingh PV, Bleeker GB, et al. (2006) Hemodynamic Effects of Long-Term 
Cardiac Resynchronization Therapy. Circulation 113: 1295–1304. 
32. ten Brinke EA, Klautz RJ, Tulner SA, Verwey HF, Bax JJ, et al. (2010) Long-term effects of surgical ventricular 
restoration with additional restrictive mitral annuloplasty and/or coronary artery bypass grafting on left 
ventricular function: Six-month follow-up by pressure-volume loops. J Thorac Cardiovasc Surg 140: 1338–1344. 
33. Thormann J (1992) The influence of clinical intervention on pressure-volume relationships—the conductance 
(volume) technique. Eur Heart J 13: 69–79. 
34. Thormann J, Hueting J, Kremer P, Wissemann J, Mitrovic V, et al. (1990) Enoximone: True inotropic effects? Do 
they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) 
Catheter technique. Cardiovascular Drugs and Therapy 4: 1403–1415. 
35. Thormann J, Kramer W, Kremer P, Schlepper M (1989) Influence of the new class-I antiarrhythmic agent 
diprafenone on the end-systolic pressure-volume relationship (conductance technique). Cardiovascular Drugs 
and Therapy 3: 145–154. 
36. Tulner SAF, Steendijk P, Klautz RJM, Bax JJ, Schalij MJ, et al. (2006) Surgical ventricular restoration in patients 
with ischemic dilated cardiomyopathy: Evaluation of systolic and diastolic ventricular function, wall stress, 
dyssynchrony, and mechanical efficiency by pressure-volume loops. Journal of Thoracic and Cardiovascular 
Surgery 132: 610–620. 
37. Urheim S, Bjornerheim R, Endresen K, Vatne K, Rabben SI, et al. (2002) Quantification of left ventricular diastolic 
pressure-volume relations during routine cardiac catheterization by two-dimensional digital echo quantification 
and left ventricular micromanometer. J Am Soc Echocardiogr 15: 225–232. 
38. Remmelink M, Delewi R, Yong ZY, Piek JJ, Baan J Jr (2010) More pronounced diastolic left ventricular dysfunction 
in patients with accelerated idioventricular rhythm after reperfusion by primary percutaneous coronary 
intervention. J Invasive Cardiol 22: 574–578. 
39. Mitchell M (2005) Engauge Digitizer. Fairfax, VA, USA. Sourceforge. Accessed on 2/7/12. Available: 
http://digitizer.sourceforge.net/index.php?c57. 
40. ShiY (2007) Lumped-parameter cardiovascular model with Windkessel after-load. CellML. Auckland, NZ. 2007. 
Accessed on 2/7/12. Available: http://models.cellml.org/exposure/ea64608ab564ee085bef7cde3ed1731e. 
41. Lloyd CM, Lawson JL, Hunter PJ, Nielsen PF (2008) The CellML Model Repository. Bioinformatics 24: 2122–2123. 
 PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 22 / 22 
Closing the Loop 
42. Hayward CS, Kalnins WV, Kelly RP (2001) Gender-related differences in left ventricular chamber function. 
Cardiovascular Research 49: 340–350. 
